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ABSTRACT
Merkel cell carcinoma (MCC) is a rare, highly aggressive neuroendocrine skin 
cancer. In more than 80% of the cases, Merkel cell polyomavirus (MCPyV) is a causal 
factor. The oncogenic potential of MCPyV is mediated through its viral oncoproteins, 
large T antigen (LT) and small t antigen (sT). To investigate the role of cytokines in 
MCC, a PCR array analysis for genes encoding inflammatory cytokines and receptors 
was performed on MCPyV-negative and MCPyV-positive MCC cell lines, respectively. We 
detected an increased expression of CCL17/TARC in the MCPyV-positive MKL2 cell line 
compared to the MCPyV-negative MCC13 cell line. Transfection studies in MCC13 cells 
with LT expression plasmid, and a luciferase reporter plasmid containing the CCL17/
TARC promoter, exhibited stimulated promoter activity. Interestingly, the ectopic 
expression of CCL17/TARC upregulated MCPyV early and late promoter activities in 
MCC13 cells. Furthermore, recombinant CCL17/TARC activated both the mitogen-
activated protein kinase and the NF-κB pathways. Finally, immunohistochemical 
staining on human MCC tissues showed a strong staining of CCL17/TARC and its 
receptor CCR4 in both LT-positive and -negative MCC. Taken together, CCL17/TARC 
and CCR4 may be a potential target in MCC therapy providing MCC patients with a 
better overall survival outcome.
INTRODUCTION
Merkel cell carcinoma (MCC) is a rare, highly 
aggressive neuroendocrine skin cancer [1, 2]. In 2008, 
using digital transcriptome subtraction, a new virus 
belonging to the family of Polyomaviruses, and hence 
named Merkel cell polyomavirus (MCPyV), was 
identified in MCC. Worldwide studies have shown 
that approximately 80% of all examined MCC contain 
clonal integrated MCPyV DNA [3], thus indicating that 
MCPyV is associated with the etiology of MCC [4, 5]. 
MCPyV has a circular, double-stranded DNA genome of 
approximately 5.4 kb [6]. The viral genome possesses 
the typical polyomavirus tripartite organization, with 
an early region encoding the regulatory proteins large 
T (LT) antigen and small T (sT) antigen [7], the late 
region encoding the capsid proteins [8], and a non-
coding control region encompassing the origin of 
replication and transcription regulatory elements [9]. In 
addition, the early region encodes the 57kT antigen and 
a protein called alternative LT ORF (ALTO), although 
their function remains unknown [7]. All MCPyV-positive 
(MCPyV+) MCC express a C-terminal truncated form 
of LT antigen that has lost its DNA binding and p53 
interaction domains, but retains the ability to interact 
with retinoblastoma protein pRb [10]. Both sT and full-
length LT, as well as truncated LT, have been shown 
to possess oncogenic potential in both cell culture and 
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animal models [11-14]. The proliferation of MCC cell 
lines depends on the expression of LT [15], while the role 
of sT has been disputed [16, 17].
Inflammation has long been associated with 
tumor progression [18]. Many cancers arise from sites 
of infection, chronic irritation and inflammation, and 
inflammatory signaling pathways are often activated 
by oncogenic mutations [19]. Chemokines are a family 
of cytokines that regulate leukocyte trafficking in 
immunity and inflammation, playing a significant 
role in processes attributed to tumorigenesis, such 
as tumor cell survival, senescence, angiogenesis, 
metastasis and immune escape. The aberrant expression 
of chemokines and chemokine receptors in tumors 
may regulate the trafficking of leukocytes into the 
tumor microenvironment [20]. Chemokines secreted 
within the tumor microenvironment may also act in 
an autocrine manner to promote the proliferation and 
migration of the tumor cells. Chemokine (C-C motif) 
ligand 17/thymus and activation-regulated (CCL17/
TARC) is a member of the CC chemokine family, and 
is highly expressed by thymus and other cells, including 
keratinocytes, endothelial cells, dendritic cells, 
bronchial epithelial cells and fibroblasts [21]. CCL17/
TARC acts as a chemoattractant, which primarily aids 
the recruitment of CD4+ T regulatory cells and Th2, in 
addition to Th17 cells [22, 23]. The effect of CCL17/
TARC is mediated by the chemokine receptor CCR4 
[24, 25].
In this study we compared the cytokine expression 
pattern in MCPyV-positive with MCPyV-negative MCC 
cells and examined the role of the viral protein LT on 
cytokine expression. In addition, we investigated whether 
cytokines have an impact on viral expression.
RESULTS
Differential expression profile of inflammatory 
modulators in MCPyV-negative and MCPyV-
positive MCC cell lines
Inflammatory mediators such as cytokines are 
known to play a role in cancer. This prompted us to 
compare the expression of 84 inflammatory cytokines and 
cytokine receptors in a MCPyV-negative (MCC13) and a 
MCPyV-positive MCC cell line (MKL-2), respectively. 
All 84 human inflammatory cytokines and receptor 
transcripts were detectable (Cq < 35) by RT profiler 
PCR array. Out of 84 transcripts, with the fold changes 
critical value set ≥ 2 fold differentiated, the expression of 
11 (13.09%) were upregulated and the expression of 18 
(21.42%) were downregulated in MKL-2 cells compared 
with MCC13 cells, while 55 (65.47%) of the genes had 
comparable transcription levels in both cell lines (Figure 
1A) (data not shown).
Expression analysis of cytokines and their 
receptor in MCPyV-negative MCC13 cells and 
MCC13 cells transiently expressing exogenous 
LT
Because the LT of polyomaviruses is known to 
affect viral and cellular gene expression (30), we wanted 
to examine whether LT may be responsible for the 
differential expression of cytokines and their receptors in 
these MCC cell lines [10, 26]. Therefore, the eukaryotic 
expression vectors for MKL-2 LT, but also for the LT 
of two other virus-positive MCC cell lines (MKL-1 and 
MS-1), were generated. These virus-positive expression 
plasmids containing full-length LT and truncated LT 
(MKL-1, MKL-2 and MS-1) were then confirmed by 
sequencing (Supplementary Figure 1). A Western blot 
of lysates from MCC13 cells transfected with these 
expression plasmids confirmed the presence of LT with a 
correct predicted molecular mass (Supplementary Figure 
2). Next, we transfected MCC13 cells with pcDNA3-full-
length LT, pcDNA3-MKL-2, or empty vector pcDNA3 
as a control, and measured the transcript levels of the 
84 inflammatory cytokines and receptors by qPCR. For 
cells transfected with full-length LT expression plasmid, 
71 out of 84 human inflammatory cytokines and receptor 
transcripts were detectable (Cq < 35), whereas the 
transcript for the remaining 13 genes was undetectable 
or had Cq values ≥ 35 by RT profiler PCR array. Out of 
84 transcripts, with the fold changes critical value set ≥ 
2, 8 (9.52%) genes were upregulated, while 76 (90.48%) 
genes did not show any effect or undetectable compared 
with empty vector transfected cells (Figure 1B) (data not 
shown). For cells transfected with MKL-2 truncated LT 
expression plasmid, 70 out of 84 human inflammatory 
cytokines and receptor transcripts were detectable (Cq 
< 35), while of the remaining, 14 were undetectable or 
had Cq values ≥ 35 by RT profiler PCR array. Out of 
84 transcripts, with the fold changes critical value set ≥ 
2, 32 (38.09%) genes were upregulated and 4 (4.76%) 
genes were downregulated, while 48 (57.14%) genes 
did not show any effect or undetectable compared with 
the control cells (data not shown) compared to MCC13 
cells transfected with an empty vector (Figure 1C). One 
of the genes whose transcript levels were consistently 
upregulated in MKL-2 cells, and in MCC13 cells 
transiently expressing full-length or truncated MKL-2 LT 
compared to MCC13 cells, was CCL17/TARC.
MCPyV large T antigen induces CCL17/TARC 
promoter activity
Because CCL17/TARC expression was shown to 
be upregulated in cells that were either MCPyV-positive 
or that expressed a full-length or truncated LT, we tested 
whether MCPyV LT could induce CCL17/TARC promoter 
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activity. For this purpose, MCC13 cells were transiently 
co-transfected with a plasmid encoding a full-length or 
truncated LT (MKL-1, MKL-2 and MS-1), and with a 
luciferase reporter driven by different fragments of the 
CCL17/TARC promoter (fragment -2535/+ 40, -1084/+ 
40 or -378/+40, respectively). The empty vector pcDNA3 
was used as a control. Full-length, as well as the truncated 
LT versions MKL-1 and MS-1 significantly stimulated 
the CCL17/TARC promoter activity. The largest CCL17/
TARC promoter fragment (-2535/+40) was more potently 
activated than the shorter promoter fragments (-1084/+40 
and -375/+40, respectively) by LT MKL-1 and MS-1, 
while comparable full-length LT-mediated transactivation 
the three different CCL17/TARC promoter fragments. 
MKL-2 LT significantly stimulated the activity of the 
CCL17/TARC promoter encompassing nucleotides 
-2535/+40 and -375/+40, but induced only slightly, but 
statistically insignificant the CCL17/TARC -1080/+40 
promoter sequence (Figure 2). These results confirm the 
qPCR data showing that CCL17/TARC expression is 
higher in LT expressing MCC13 compared to MCC13 
cells. The enhanced CCL17/TARC transcript levels in 
MKL-2 cells, compared to the virus-negative MCC13 
cells, may at least be partially triggered by LT. In contrast, 
Figure 1: Relative expression comparison of 84 inflammatory cytokines and receptors genes between MCPyV-
associated and non-associated Merkel cell carcinoma. The figures depict a log transformation plot of the relative expression level 
of each gene (2-ΔCt) between (A) MCC13 cells vs. MKL-2 cells, (B) full-length LT vs. empty vector transfection in MCC13 cell line and 
(C) MKL-2 truncated LT vs. empty vector transfection in MCC13 cell line. The dotted lines indicate a two-fold change in gene expression 
threshold.
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sT did not stimulate the activity of any of the CCL17 
promoter fragments or increase sT protein levels when 
expressed in MCC13 cells (results not shown).
CCL17/TARC ectopic effect on MCPyV early 
and promoter activity
Cytokines such as IL-1β, TGF β and TNF-α have 
been shown to stimulate the activity of human polyomavirus 
promoters [27-30]. Therefore, we investigated whether 
CCL17/TARC could exert an effect on the MCPyV early 
and late promoter activity. MCC13 cells were transfected 
with a luciferase reporter plasmid containing, either the 
early or late MCPyV promoter, and cells were either co-
transfected with a CCL17/TARC expression plasmid 
or treated with recombinant human CCL17/TARC 
protein. Both an ectopic expression of CCL17/TARC 
and administering of recombinant CCL17/TARC to cells 
resulted in a significant upregulation of both the early and 
late MCPyV promoter activity (Figure 3).
Expression of CCL17/TARC and CCR4 in MCC 
cells
To confirm the stimulating effect of full-length and 
truncated LT on CCL17/TARC promoter activity, we 
first evaluated the mRNA expression of CCL17/TARC 
by qPCR in MCC13 cells transfected with expression 
vector for full-length LT or truncated LT variants. Full-
length and MKL-1 LT significantly increased CCL17/
TARC expression in the MCC13 cell line (P < 0.01), while 
MKL-2 and MS-1 LT variants, modestly, but significantly 
increased CCL17/TARC mRNA levels (Figure 4A). 
Western blot analysis with anti-CCL17/TARC antibodies 
confirmed that CCL17/TARC protein levels were 
increased in MCC13 cells expressing either full-length or 
truncated LT compared to MCC13 cells (Figure 4B and 
4D). In our screening experiments, we also found a slight 
upregulation of CCR4 mRNA by exogenous expression of 
both pcDNA3-FLTA and pcDNA3-MKL-2 plasmids. So, 
to check at the protein level, we conducted a Western blot. 
Figure 2: Effect of full-length and truncated (MKL-1, MKL-2 and MS-1) LT on CCL17/TARC promoter activity in 
MCC13 cells. Cells were transfected with a luciferase reporter vector driven by CCL17/TARC promoter fragments spanning 
nucleotides -2535/+ 40, -1084/+ 40 or -375/+40, respectively. Expression plasmid for full-length LT (FLTA), MKL-1, MKL-
2 or MS-1 LT, or pcDNA3 control, were co-transfected. Luciferase activity was assessed after an overnight cultivation of 
transfected cells. The promoter activity in presence of pcDNA3 was arbitrary set as 1.0 and the promoter activity measured 
in the presence of LT was related to this. Each bar represents the average of three independent parallels +SD. The experiment 
was repeated two more times, and similar results were obtained. Luciferase values were normalized with a total protein in 
each sample. P* ≤ 0.05, P** ≤ 0.01, P*** ≤ 0.001 and P**** ≤ 0.0001.
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We did not find expression at a significant level, but only 
a slight upregulation of CCR4 in MCC13 cells with an 
exogenous expression of MCPyV LT (Figure 4C and 4D).
CCL17/TARC activates the mitogen-activated 
protein kinase (MAP kinase) and NF-κB 
pathways in MCC cells
Both CCL17/TARC and ERK1/2 have been shown 
to be involved in skin inflammation [31-33], thereby 
suggesting that CCL17/TARC may activate the MEK1/2-
ERK1/2 mitogen-activated protein kinase pathway. To 
help investigate the effect of CCL17/TARC on MEK1/2-
ERK1/2 activation in MCPyV-associated MCC, we 
stimulated MCC13 cells with recombinant human 
CCL17/TARC. The cells were stimulated with different 
concentrations (2.5 ng/ml to 15 ng/ml) and time periods 
(5 min to 60 min) and we monitored the phosphorylation 
of ERK1/2 using phospho-specific antibodies and western 
blotting. Activation of ERK1/2 by rhCCL17/TARC was 
shown to be concentration dependent (Figure 5). The 
ERK1/2 phosphorylation activity was inhibited by using a 
specific CCR4 antagonist (C021 dihydrochloride) (Figure 
6).
Previous studies have indicated that NF-κB is 
a target downstream of CCL17/TARC. We found that 
CCL17/TARC increased the phosphorylation of NF-κB/
p65 activity in a concentration-dependent manner (Figure 
7A, 7B), which was inhibited by using a specific CCR4 
antagonist (Figure 7D, 7E). Furthermore, NF-κB promoter 
assay confirmed an increased luciferase activity of NF-κB 
when cells were co-transfected with pCMV2-CCL17 and 
NF-κB-luc reporter plasmids (Figure 7C).
CCL17/TARC stimulates cell proliferation of 
MCC13 cells
Next, we examined the effect of rhCCL17/TARC 
on MCC13 proliferation. A dose-dependent increase in 
cell proliferation was observed (Figure 7F). The CCR4 
antagonist C021 inhibited CCL17/TARC-induced cell 
proliferation (Figure 7G).
CCL17/TARC and its receptor are expressed in 
MCC tissue samples
A total of 23 primary cutaneous MCCs were 
immunohistochemically stained for LT, CK20, CCL17/
TARC and CCR4, respectively. Fifteen out of 23 (65.2%) 
demonstrated an intranuclear positivity consistent with 
a positivity for LT. All of the 15 LT-positive tumors 
demonstrated a uniform positivity for CK20 (dot-like 
cytoplasmic) and CCL17/TARC (dot-like cytoplasmic). 
With regard to CCR4, 12 out of 15 (80%) of the LT-
positive tumors demonstrated cytoplasmic, membranous 
positivity for CCR4. Of the remaining eight (34.8%) 
LT -negative tumors, all of these demonstrated a 
uniform positivity for CK20, CCL17/TARC and CCR4, 
respectively (Figure 8).
DISCUSSION
There is increasing evidence that inflammatory 
mediators such as chemokines and chemokine receptors 
are involved in promoting tumor invasion, migration and 
vascularization [34]. Previous studies have demonstrated 
the involvement of chemokines, such as CXCL1, CXCL5, 
Figure 3: CCL17/TARC stimulates MCPyV early and late promoter activity. (A) MCC13 cells were seeded, and after 24 hrs 
the cells were serum starved. After serum starvation for 24 hrs, the cells were co-transfected with either CCL17/TARC expression plasmid 
or empty expression vector pcDNA3.1, and luciferase reporter plasmid containing either the MCPyV early or the late promoter. Luciferase 
activity was measured 24 hrs after transfection. The activity of the MCPyV early (respectively late) promoter in the presence of pcDNA3 
was arbitrary set as 1.0 and the activity in the presence of CCL17 was related to this. (B) Cells were transfected as in (A), and were then 
exposed to rhCCL17/TARC (12ng/ml) or vehicle (PBS) for 4 hrs with a subsequent analysis of luciferase activity. Each bar represents the 
average of three independent parallels +SD*P < 0.05, ***P < 0.001.
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CXXC4 and IL20RA in MCPyV-associated MCC [35]. In 
the current study, we performed the screening of different 
inflammatory cytokines and receptors, and compared 
their expression in MCPyV LT-positive and -negative 
MCC, respectively. Other groups have previously reported 
that LT and sT have an impact on cytokine expression. 
Ectopic sT expression in MCC13 cells resulted in 
decreased IL2, IL-8, CCL20 and CXCL9 expression 
[36]. Also, expression of full-length LT, truncated LT339, 
and truncated LT339 plus sT in hTERT-immortalized BJ 
human foreskin fibroblasts increased the expression of IL-
1β, IL-6, IL-8, CXCL1 and CXCL6 [37].
Here we demonstrate that one of the cytokine 
member whose expression was shown to be significantly 
enhanced in MCPyV LT-positive cells was CCL17/TARC. 
CCL17/TARC is a member of CC-motif chemokine 
family, and is constitutively expressed in thymus and 
by dendritic cells, endothelial cells, keratinocytes and 
fibroblasts [38]. An enhanced expression of CCL17/
TARC has been reported in several human malignancies, 
such as Hodgkin’s and B cell lymphoma [39, 40]. Previous 
studies have revealed that CCL17/TARC possesses several 
important effects attributed to tumor growth, such as 
the proliferation [41-43], migration and recruitment of 
regulatory T-cells [44-46].
We detected a higher expression of CCL17/
TARC in MCPyV-positive MCC compared to MCPyV-
negative MCC cells at both the RNA and protein level. 
Furthermore, by co-transfecting MCC cells with MCPyV 
full LT, MKL-1 LT, MKL-2 LT and MS-1 LT expression 
plasmids, as well as CCL17/TARC promoter, resulted 
in an upregulation of CCL17/TARC promoter activity 
(Figure 2), which in turn increased the expression of 
CCL17/TARC (Figure 4). At present, we do not know 
why the different LT variants activate the CCL17 promoter 
at different levels. MCPyV full-length LT can interact 
with several transcription factors including Brd4, the 
E2F family members 2 and 3, MED14/CRSP2, PRTF1, 
Figure 4: Transient expression of full-length or truncated MCPyV LT increases the transcript and protein levels 
of CCL17/TARC. MCC13 cells were transfected with an empty vector or expression plasmid for MCPyV full-length LT (FLTA), or 
truncated MKL-1, MKL-2, or MS-1 LT. (A) qRT-PCR analysis shows CCL17/TARC mRNA levels normalized with eukaryotic 18S rRNA 
levels. (B) CCL17/TARC protein levels analyzed by Western blotting. The uttermost right lane represents baseline expression of CCL17/
TARC by MCC13 cells. (C) CCR4 protein levels analyzed by Western blotting. A Western blot with ERK2 antibodies was used as a loading 
control. (D) Representative figures of CCL17/TARC (B) and CCR4 (C) Western blots. The lane most to the left in the lower part contains 
the protein molecular mass marker (in kDa). Bars in (B) and (C) shows a densitometric scanning of the Western blot signals. P* ≤ 0.05 and 
P*** ≤ 0.001.
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SALL2 and DP1 (see supplementary data in Moens et 
al. [47]). However, no putative binding sites are present 
in the CCL17 promoter fragments used in our study. 
The truncated MCPyV LT variants MKL-1, MKL-2 and 
MS-1 retain the pRb binding motif and may thus relieve 
the pRb-mediated inhibition of E2F by using pRb. The 
CCL17/TARC promoter contains the putative GGCGGCA 
E2F binding site at position -1085/-1079 [48]. This 
means that our luciferase reporter plasmids containing 
the CCL17/TARC promoter fragments -2535/+40 and-
1084/+40 contain this putative E2F binding site. LT 
may thus activate the CCL17/TARC promoter fragments 
with an E2F motif by usurping pRb and releasing the 
repressive effect on the E2F site. However, the shorter 
promoter fragment (-375/+40) which lacks the putative 
E2F binding site is still trans-activated by LT, indicating 
that LT-mediated activation seems to be independently 
of the E2F site. The autocrine release of CCL17/TARC 
Figure 5: CCL17/TARC upregulates ERK1/2 activity. (A) PhosphoERK1/2 (pERK1/2) expression levels were determined 
by Western blot analysis using a phospho-specific antibody detecting Thr202/Tyr204 phosphorylation and compared to total ERK1/2 
(tERK1/2) levels using an anti-pan-ERK1/2 antibody. MCC13 (1x105) cells were seeded in a 6-well plate. Cells were then serum-starved 
for 24 hrs, and thereafter stimulated with either PBS (control or C) or with 2.5, 5, 7.5, 10 and 15 ng/ml of rhCCL17/TARC for 45 min. (B) 
Densitometry scanning represent the expression of pERK1 (respectively pERK2) protein relative to GAPDH.
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results in an increase of MCPyV, both in early and late 
promoter activity, as shown by the overexpression of 
CCL17 with pCMV2-CCL17-flag plasmid and stimulation 
with recombinant CCL17/TARC (Figure 3). These data 
above indicated that MCPyV LT increases CCL17/TARC 
expression, which results in the replication of MCPyV and 
the release of viral oncoproteins, which in turn promotes 
MCC development. In line with our data, the virus-
mediated expression of CCL17/TARC has been reported 
in different types of cells. The Epstein-Barr infection of 
B cells induces the expression of CCL17/TARC [49], 
whereas the respiratory syncytial virus infection of Balb/c 
mice results in an increased CCL17/TARC production in 
the lung [50]. Hence, the virulent properties of viruses 
may depend on their ability to stimulate the expression of 
CCL17/TARC.
The role of CCR4 in tumor growth and survival 
has previously been reported. CCR4 is expressed in 
T-cell leukemia [51], non-lymphoid solid tumors, such 
as breast cancer, lung cancer, colorectal cancer, gastric 
and hepatocellular carcinoma [42, 43, 52-56], where 
it may contribute to the proliferation of tumor cells 
and chemotaxis of regulatory T cells [43, 46, 53, 57]. 
Interestingly, an elevated expression of CCR4 in different 
types of human cancers has been related to a poor 
prognosis [52, 58-61].
By immunohistochemistry, we detected CCL17/
TARC and its receptor CCR4 in the tumor cells of all 
MCC tissue samples analyzed. The normal epidermis of 
the skin was also shown to express CCL17/TARC and 
CCR4, and has been reported earlier [62-65]. We did 
not observed any difference in the protein expression 
Figure 6: The CCR4 receptor antagonist C021 reduces CCL17/TARC-induced phosphorylation of ERK1/2. (A) MCC13 
(1x105) cells were seeded in a 6-well plate and were serum starved for 24 hrs. The cells were either pre-exposed to PBS, C021 dihydrochloride 
(+), a specific CCR4 receptor antagonist, or left untreated (-) for 15 min (15’) or 30 min (30’) as indicated. The cells were subsequently 
incubated with rhCCL17/TARC (15ng/ml) or left untreated (-) for another 45 min. Cell lysates were prepared and phosphoERK1/2 and 
total ERK1/2 levels were monitored. GAPDH levels were used as loading control. Densitometry represents the expression of pERK1 
(respectively pERK2) protein relative to (B) total ERK (tERK1/2) and (C) GAPDH.
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Figure 7: CCL17/TARC upregulated NFκB activity. (A) NFκB-p65 activation was determined by monitoring phosphorylation 
of p65 and p105. MCC13 cells (1x105) were seeded in a 6-well plate. Cells were serum starved for 24 hrs, and then stimulated with 2.5, 5, 
7.5, 10 and 15 ng/ml of rhCCL17/TARC for 45 min. PBS was used as a control. Relative phospho p65 and phospho p105 were determined 
by western blot with phosphospecific antibodies. (B) Shows densitometry bars of western blot. (C) NFκB activity was measured by using 
a luciferase reporter plasmid containing a NFκB-responsive promoter. Cells were stimulated with 12ng/ml or 15ng/ml of rhCCL17/TARC 
for 4 hrs. Luciferase values were normalized with total protein. (D) The CCR4 receptor antagonist interferes with CCL17/TARC-induced 
activation of NFκB. Phospop65 and phosphor p105 levels were determined by western blot. MCC13 (1x105) cells were seeded in a 6-well 
plate and were serum starved for 24 hrs. The cells were pre-incubated with C021 dihydrochloride (0.3μM) for 30 min. The cells were then 
stimulated with rhCCL17/TARC (15ng/ml) in the presence or without CCR4 receptor antagonist for 45 min. DMSO was used as a control. 
(E) C021 ablates CCL17/TARC-induced activation of an NFκB-responsive promoter. Cells were transfected with the luciferase reporter 
plasmid with an NFκB responsive promoter and exposed to rhCCL17/TARC (15ng/ml) in the presence or without CCR4 receptor antagonist 
C012 (0.1 or 1 μM) for 45 min. DMSO was used as a control. Each bar represent the average of three independent parallels. Luciferase 
values were corrected for protein concentration of the samples. P* ≤ 0.05 and P** ≤ 0.01. (F) CCL17/TARC stimulates proliferation 
of MCC13 cells. Cell were exposed to PBS or increasing concentrations of rhCCL17/TARC /12-100 ng/ml) and cell proliferation was 
measured after 24 and 48 hrs. Each bar represents the average of three independent parallels. (G) Cells were incubated for 45 min with 0.1 
or 1 0μM C021 and rhCCL17/TARC (12 or 25 ng/ml) was subsequently added. Proliferation was monitored 24 hrs later. P* ≤ 0.05 and P** 
≤ 0.01.
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of CCR4 and CCL17/TARC between MCPyV-negative 
and MCPyV-positive primary cutaneous MCCs. Since 
immunohistochemistry is more qualitative rather than a 
quantitative analysis therefore, increase in CCL17/TARC 
levels between MCPyV-positive and -negative samples 
may not be visible by IHC.
Given the fact that MCC produces CCL17/TARC 
and expresses CCR4, we decided to investigate the effect 
of exogenously added CCL17/TARC on intracellular 
signaling pathways. Recombinant hCCL17/TARC induced 
the proliferation in MCPyV-negative MCC cells, which 
was abolished in the presence of the CCR4 receptor 
antagonist. The addition of CCL17/TARC resulted in 
ERK1/2 phosphorylation in MCC13 cells (Figure 6). 
Previous studies have shown that CCL17/TARC induced 
chemotaxis of the mouse T-cell lymphoma cell line EL4 in 
a MEK1/2-ERK1/2-dependent manner [66].
We also demonstrate that CCL17/TARC activates 
the NF-κB pathway in MCC13 cells. Previous studies 
have shown that CCL17/TARC is a NF-κB target gene 
[67, 68], but it has not been shown that CCL17/TARC 
can itself activate NF-κB. CCR4-mediated MMP13 
activity in colorectal cancer cells requires NF-κB [52]. 
Chemokine-like factor (CKLF1), which also uses the 
CCR4 receptor, can activate the NF-κB pathway [69], and 
NF-κB signaling is significantly downregulated in CCR4-
/- macrophages [70].
In the tumor microenvironment, a high expression 
of CCL17/TARC and CCR4 by MCC cells may contribute 
to the activation of inflammatory pathways and the 
promotion of tumor growth and immune suppression. 
We found that CCL17/TARC stimulated proliferation of 
MCC13 cells, whereas several studies have reported that 
CCL17/TARC or CCL22-associated CD4+CD25+Foxp3+ 
increases the population in tumor-infiltrating lymphocytes 
(TILs), with peripheral blood lymphocytes (PBLs) being 
one of the reasons for impaired anti-tumor immunity in 
both gastric and esophageal squamous cell carcinoma 
[44, 45]. It is postulated that the preferential attraction 
of CCR4-bearing Th2 lymphocytes may cause a shift 
towards a Th2-dominated cytokine microenvironment, 
thereby hampering the cytotoxic immune response and 
providing a mechanism by which neoplastic cells are able 
to escape from the immune system [71]. Targeting CCR4 
is an emerging strategy for immunotherapy for cancer [57, 
72]. Gain-of-function mutations in adult T cell lymphoma 
have been reported [73] and recently, Mogalizumab, a 
monoclonal antibody targeting CCR4 receptor has shown 
promising results in the treatment of relapsed adult T cell 
lymphoma patients [74-78].
Taken together, we demonstrate that MCPyV LT is 
linked with an altered expression of CCL17/CCR4. The 
expression of CCL17/TARC and CCR4 may constitute an 
autocrine or paracrine survival loop which contributes to 
the growth and survival of the tumor, and also mediates 
immune suppression through the recruitment of regulatory 
T cells. Thus, strategies based on the selective targeting of 
the CCL17/CCR4 axis, either by monoclonal antibodies 
or specific receptor antagonists, could be a therapeutic 
interventions for patients with MCC.
Figure 8: Immunoperoxidase staining of MCPyV-associated MCC primary tumors. (A) HE, (B) CCL17/TARC, (C) CCR4, 





In our study, the following primary antibodies were 
used: i.e. monoclonal mouse MCPyV LTA (Sc-136172, Santa 
Cruz Biotechnologies), polyclonal rabbit CCL17/TARC (Ab-
182793, Abcam), polyclonal rabbit anti-CCR4 (cat.#PA1516, 
Boster, USA), polyclonal rabbit ERK2 (Sc-136172, Santa 
Cruz Biotechnologies, Dallas, TX, USA), monoclonal 
rabbit keratin 20 (cat.# 13063, Cell Signaling, Danvers, MA, 
USA), monoclonal rabbit Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (cat.#4370 Cell Signaling), monoclonal 
rabbit p44/42 MAPK (Erk1/2) (cat.#4695S, Cell Signaling), 
Phospho-NF-κB p105 (Ser933) (18E6) (cat.#4806S, Cell 
Signaling) rabbit anti-GAPDH (cat.# G9545, Sigma Aldrich, 
St. Louis, MO, USA) and CCR4 chemokine receptor 
antagonist (C 021 dihydrochloride) (cat. #3581, Tocris 
Bioscience Minneapolis, MN, USA)).
Plasmids
The empty expression plasmid pcDNA3.1(+) was 
purchased from Invitrogen. pcDNA3-full large T-antigen 
(pcDNA6.MCV.cLT206.V5_CM2B4) was purchased from 
Addgene (Cambridge, MA, USA), while pcDNA3-MKL-1 
large T-antigen, pcDNA3-MKL-2 large T-antigen and 
pcDNA3-MS-1 large T-antigen were constructed by site-
directed mutagenesis using the original pcDNA6.MCV.
cLT206.V5_CM2B4 plasmid. pCMV2-CCL17-flag (cat.# 
HG10233-M-F) expression plasmid was purchased from 
SinoBiological (Beijing, China). The plasmids pCCL17-
2532+40-LUC, pCCL17-1080/+40-LUC, and pCCL17-
375/+40-LUC containing CCL17 promoter fragments in 
the luciferase reporter plasmid pGL3-basic (Promega) 
were a kind gift from Dr. Daniel Hebenstreit [79].
Cell lines and human tissue samples
MCC13 and MKL-2 cell lines were kindly provided 
by Dr. Baki Akgül (University of Cologne, Germany). 
MCC13 is a MCPyV-negative MCC cell line, whereas 
MKL-2 is a MCPyV-positive MCC cell line [58, 59]. 
MCC13 cells were grown in RPMI-1640 with 10% 
FBS in the presence of 100 μg/ml streptomycin and 100 
units/ml of penicillin, while MKL-2 cells were grown in 
RPMI-1640 with 20% FBS in the presence of 100 μg/
ml streptomycin and 100 units/ml penicillin. Cells were 
kept in a humidified CO2 incubator at 37
oC. Human MCC 
tissue were obtained during 2000-2015 from the St. Olavs 
University Hospital Trondheim, Norway according to the 
ethical approval from the Regional Ethical Committee 
(REK NORD application number 2016/988).
PCR-based site-directed mutagenesis of MCPyV 
truncated LT encoding plasmid
To generate expression plasmids encoding 
truncated variants of MCPyV LT expressed in the virus-
positive MKL-1, MKL-2 and MS-1 MCC cell lines, an 
oligonucleotide-directed mutagenesis was performed 
using the QuickChange site-directed mutagenesis kit from 
Stratagene (cat. no. 200518; Stratagene La Jolla, CA, 
USA). Plasmid pcDNA6.MCV.cLT206.V5 was used as a 
template to generate the plasmids pcDNA3-MKL-1 LT, 
pcDNA3-MKL-2 LT, pcDNA3-MS-1 LT. Table 1 shows 
different primers to generate truncated MKL-1, MKL-2 
and MS-1 sequences from full-length LT.
Table 1: Primer sequences for full-length LT and generating truncated Large Tag transcripts
MCPyV full-length LT sequence primers
Full_LT.F 5′-TACAAGCACTCCACCAAAGC-3′
Full_LT.R 5′-TCCAATTACAGCTGGCCTCT-3′














Cells were seeded out in 6- and 12-well cell 
culture plates with a total number of 1.5x105 and 2x105, 
respectively. At the time of transfections, the cells were 
approximately 60-70% confluent. jetPRIME (Polyplus-
transfection SA, Illkirch, France) was used to transfect all 
plasmids according to the manufacturer’s instructions. A 
total of 2-μg per well in a 6-well plate and 800 ng per 
well in a 12-well plate DNA was used to transfect cells. 
All experiments were performed 24 hrs after transfection.
RNA extraction
RNA extraction was done by using RNeasy® Plus 
Mini kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. For RNA yield and quality, A260/
A280 and A260/A230 ratios were analyzed with Nano-Drop® 
ND-2000 spectrophotometer (NanoDrop Technologies, 
ThermoFisher Scientific, Waltham, MA, USA).
cDNA construction and quality control
iScript™ cDNA Synthesis Kit (BioRad, Hercules, 
CA, USA) was used to make cDNA. A total of 1-2 μg 
RNA was used to generate cDNA according to the 
manufacturer‘s instructions. PCR with the housekeeping 
APRT primers (5’- CCCGAGGCTTCCTCTTTGGC-3’ 
and 5’-CTCCCTGCCCTTAAGCGAGG-3’) were used 
to check for genomic DNA contamination in the cDNA 
prep. An 800 bp fragment was obtained with genomic 
DNA as a template, while a 300 bp amplicon was obtained 
with cDNA (76). PCR products were visualized on a 1% 
agarose gel stained with GelredTM Nucleic Acid Gel Stain 
gel red stain (Biotium, Cambridge Bioscience, Bar Hill, 
UK).
RT2 Profiler PCR array
A human cytokines and receptor genes transcription 
was measured using the human RT2 Profiler PCR 
Inflammatory Cytokines and Receptors Array (PAHS-
011ZA, SABiosciences, Qiagen). Twenty μl cDNA were 
diluted to 111 μl by adding 91 μl of RNase-free water. 
One hundred and two μl were added in a 1350 μl 2x RT2 
SYBR Green Mastermix according to the manufacturer’s 
protocol. Twenty-five μl PCR components mix was added 
to each well of a 96-well plate. A two-step real-time PCR 
was initiated at 95oC (10 min) for one cycle, and followed 
by alteration of 95oC (15 sec) and 60oC (1 min) for 45 
cycles by using Light Cycler 96 (Roche Diagnostics, 
Indianapolis, IN, USA). All data was collected from 
the PCR machine by Light Cycler 96 SW 1.1 software 
(Provided by manufacturer), and analyzed by SA 
Bioscience’s Gene Glob PCR Array Data Analysis Web 
Portal. For considering a gene differentially expressed, we 
used a differential cut-off of 2-fold (up- or downregulated).
Luciferase assays
For luciferase assays, approximately 24 hrs after 
transfection, cells were lysed in a 100 μl Luciferase Assay 
Tropix Lysis solution (ThermoFisher Scientific), with 0.5 
mM DTT. Cells were scraped, transferred to Eppendorf 
tubes and then centrifuged for 3 minutes at 12,000 g. Twenty 
μl of the supernatant was used in a 96-well microtiter plate, 
and a 50 μl luciferase buffer (Promega, Madison, WI, USA) 
was added. A Luminometer (Labsystem, Luminoscan RT) 
used to measure lights units. Each experiment was repeated 
three times with three independent parallels for each 
experiment, and luciferase values were corrected for protein 
content in each sample. The total protein concentration 
was measured using the MN protein quantification assay 
(Macherey-Nagel GmbH, Düren, Germany).
Quantitative real-time PCR
The gene expression level of CCL17/TARC was 
measured by real-time quantitative RT-PCR using an 
ABI PRISM® 7300 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). The expression 
level was measured by using a FAM-labeled TaqMan 
gene expression assay CCL17/TARC probe/primer 
(Cat. # Hs00171074_m1), and the expression level was 
normalized by using a VIC/MGB probe/primer Eukaryotic 
18S rRNA Endogenous Control (Cat. #4319413E, Applied 
Biosystems). PCR reactions were prepared in a total 
volume of 25 μl, with a final concentration of 1X TaqMan® 
Universal Master Mix and cDNA from 1 μg total RNA.
Immunoblotting
Western blot was done by running samples in 
4-12% of NuPAGE Bis-Tris Mini Gels (Invitrogen Life 
Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s protocol and blotted onto a 0.45 μm PVDF 
membrane (Millipore, Billerica, MA, USA). Membrane 
blocking was performed by using TBS-T (TBS with 
0.1% Tween-20; Sigma Aldrich) containing 5% (w/v) 
dried skimmed milk for 1 hour. The protein was probed 
by using an appropriate primary antibody overnight at 
4°C. After washing the membrane 3 times with TBS-T, 
an appropriate secondary antibody was added for 1 hour 
at room temperature. After 2 washes with TBS-T and 2 
washings with washing buffer, antigen-antibody complex 
was visualized by using SuperSignal™ West Pico 
Chemiluminescent Substrate (Cat.#34080 Thermo Fisher 
Scientific, Rockford, IL, USA). Magic-Mark™ Western 
standard from Invitrogen Life Technologies was used to 
estimate the molecular mass of the detected proteins.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue 
sections were deparaffinized in xylene and graded alcohols, 
hydrated and washed in PBS. After antigen retrieval in 
Oncotarget31444www.oncotarget.com
a sodium citrate buffer (pH 6) in a microwave oven, the 
endogenous peroxidase was blocked by 0.3% H2O2 for 15 
min. Sections were incubated overnight at 4°C with the 
primary antibody CCR4 (Abcam Cat.#ab1699, Cambridge, 
UK), CCL17/TARC (Abcam Cat.#ab182793), MCPyV-LT 
(Santa Cruz Biotechnology Cat.#sc-136172) and CK20 
(Roche Cat.#790-4431). As a secondary antibody, the anti-
rabbit-HRP SuperPicTure Polymer detection kit (87-9663, 
Zymed-Invitrogen, San Francisco, CA, USA) or anti-mouse 
EnVision-HRP (Dako, Agilent Technologies, Inc., Santa 
Clara, CA, USA) was used. A matched isotype control was 
used as a control for nonspecific background staining.
MTT assay
To measure cell proliferation, the colorimetric MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazodium 
bromide)-assay was used [80].
Statistical analysis
The RT2 Profiler PCR Array data analysis version 3.5 
(http://dataanalysis.sabiosciences.com/pcr/arrayanalysis.php) 
was used for inflammatory cytokines and receptor data 
analysis. For the analysis, the significant values were 
considered with a fold change/fold regulation ≥2 and a 
p-value less than 0.05. GraphPad software was used for the 
statistical analysis and graphs. The sample t-test was used to 
compare differences between the experimental and control 
group and a p-value set <0.05. The densitometry analysis of 
Western blot was done by using imageJ.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This study was funded with grants from the 
University of Tromsø, Erna and Olav Aakre Foundation 
for Cancer Research Tromsø, The Olav Raagholt og Gerd 
Meidel Raagholt Research Foundation, Norway and Odd 
Fellow Research foundation, Norway.
REFERENCES
1. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang 
LC, Penas PF, Nghiem P. Clinical characteristics of 
Merkel cell carcinoma at diagnosis in 195 patients: the 
AEIOU features. J Am Acad Dermatol. 2008; 58:375-81. 
https://doi.org/10.1016/j.jaad.2007.11.020.
2. Poulsen M. Merkel-cell carcinoma of 
the skin. Lancet Oncol. 2004; 5:593-9. 
https://doi.org/10.1016/S1470-2045(04)01593-1.
3. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a 
polyomavirus in human Merkel cell carcinoma. Science. 2008; 
319:1096-100. https://doi.org/10.1126/science.1152586.
4. Chang Y, Moore PS. Merkel cell carcinoma: a virus-
induced human cancer. Annu Rev Pathol. 2012; 7:123-44. 
https://doi.org/10.1146/annurev-pathol-011110-130227.
5. Samimi M, Touze A. Merkel cell carcinoma: the 
first human cancer shown to be associated with 
a polyomavirus. Presse Med. 2014; 43:e405-11. 
https://doi.org/10.1016/j.lpm.2014.09.008.
6. Gjoerup O, Chang Y. Update on human polyomaviruses 
and cancer. Adv Cancer Res. 2010; 106:1-51. 
https://doi.org/10.1016/S0065-230X(10)06001-X.
7. Carter JJ, Daugherty MD, Qi X, Bheda-Malge A, Wipf 
GC, Robinson K, Roman A, Malik HS, Galloway DA. 
Identification of an overprinting gene in Merkel cell 
polyomavirus provides evolutionary insight into the birth 
of viral genes. Proc Natl Acad Sci U S A. 2013; 110:12744-
9. https://doi.org/10.1073/pnas.1303526110.
8. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, 
Moschos S, Chang Y, Buck CB, Moore PS. Human Merkel 
cell polyomavirus infection II. MCV is a common human 
infection that can be detected by conformational capsid 
epitope immunoassays. Int J Cancer. 2009; 125:1250-6. 
https://doi.org/10.1002/ijc.24509.
9. Feng H, Kwun HJ, Liu X, Gjoerup O, Stolz DB, Chang 
Y, Moore PS. Cellular and viral factors regulating Merkel 
cell polyomavirus replication. PLoS One. 2011; 6:e22468. 
https://doi.org/10.1371/journal.pone.0022468.
10. Wendzicki JA, Moore PS, Chang Y. Large T and small T 
antigens of Merkel cell polyomavirus. Curr Opin Virol. 2015; 
11:38-43. https://doi.org/10.1016/j.coviro.2015.01.009.
11. Shuda M, Guastafierro A, Geng X, Shuda Y, Ostrowski SM, 
Lukianov S, Jenkins FJ, Honda K, Maricich SM, Moore 
PS, Chang Y. Merkel cell polyomavirus small T antigen 
induces cancer and embryonic merkel cell proliferation in 
a transgenic mouse model. PLoS One. 2015; 10:e0142329. 
https://doi.org/10.1371/journal.pone.0142329.
12. Verhaegen ME, Mangelberger D, Harms PW, Vozheiko 
TD, Weick JW, Wilbert DM, Saunders TL, Ermilov AN, 
Bichakjian CK, Johnson TM, Imperiale MJ, Dlugosz AA. 
Merkel cell polyomavirus small T antigen is oncogenic in 
transgenic mice. J Invest Dermatol. 2015; 135:1415-24. 
https://doi.org/10.1038/jid.2014.446.
13. Spurgeon ME, Cheng J, Bronson RT, Lambert PF, 
DeCaprio JA. Tumorigenic activity of merkel cell 
polyomavirus T antigens expressed in the stratified 
epithelium of mice. Cancer Res. 2015; 75:1068-79. 
https://doi.org/10.1158/0008-5472.CAN-14-2425.
14. Verhaegen ME, Mangelberger D, Harms PW, Eberl M, 
Wilbert DM, Meireles J, Bichakjian CK, Saunders TL, 
Wong SY, Dlugosz AA. Merkel cell polyomavirus small 
T antigen initiates merkel cell carcinoma-like tumor 
development in mice. Cancer Res. 2017; 77:3151-7. 
https://doi.org/10.1158/0008-5472.CAN-17-0035.
15. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, 
Angermeyer S, Henzel K, Hauser S, Elling R, Brocker 
Oncotarget31445www.oncotarget.com
EB, Gaubatz S, Becker JC, Schrama D. An intact 
retinoblastoma protein-binding site in Merkel cell 
polyomavirus large T antigen is required for promoting 
growth of Merkel cell carcinoma cells. Int J Cancer. 2012; 
130:847-56. https://doi.org/10.1002/ijc.26076.
16. Angermeyer S, Hesbacher S, Becker JC, Schrama D, 
Houben R. Merkel cell polyomavirus-positive Merkel 
cell carcinoma cells do not require expression of the viral 
small T antigen. J Invest Dermatol. 2013; 133:2059-64. 
https://doi.org/10.1038/jid.2013.82.
17. Shuda M, Chang Y, Moore PS. Merkel cell polyomavirus-
positive Merkel cell carcinoma requires viral small 
T-antigen for cell proliferation. J Invest Dermatol. 2014; 
134:1479-81. https://doi.org/10.1038/jid.2013.483.
18. Nagarsheth N, Wicha MS, Zou W. Chemokines in the 
cancer microenvironment and their relevance in cancer 
immunotherapy. Nat Rev Immunol. 2017; 17:559-72. 
https://doi.org/10.1038/nri.2017.49.
19. Zamarron BF, Chen W. Dual roles of immune cells and their 
factors in cancer development and progression. Int J Biol 
Sci. 2011; 7:651-8.
20. Grivennikov SI, Greten FR, Karin M. Immunity, 
inflammation, and cancer. Cell. 2010; 140:883-99. 
https://doi.org/10.1016/j.cell.2010.01.025.
21. Saeki H, Tamaki K. Thymus and activation 
regulated chemokine (TARC)/CCL17 and 
skin diseases. J Dermatol Sci. 2006; 43:75-84. 
https://doi.org/10.1016/j.jdermsci.2006.06.002.
22. Kubo T, Ichimiya S, Tonooka A, Nagashima T, Kikuchi T, 
Sato N. p63 induces CD4+ T-cell chemoattractant TARC/
CCL17 in human epithelial cells. J Interferon Cytokine Res. 
2008; 28:725-32. https://doi.org/10.1089/jir.2008.0035.
23. Gilet J, Chang Y, Chenivesse C, Legendre B, Vorng H, 
Duez C, Wallaert B, Porte H, Senechal S, Tsicopoulos 
A. Role of CCL17 in the generation of cutaneous 
inflammatory reactions in Hu-PBMC-SCID mice grafted 
with human skin. J Invest Dermatol. 2009; 129:879-90. 
https://doi.org/10.1038/jid.2008.333.
24. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge 
RC, Kupper TS. The majority of human peripheral blood 
CD4+CD25highFoxp3+ regulatory T cells bear functional 
skin-homing receptors. J Immunol. 2006; 177:4488-94.
25. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells 
share major trafficking receptors with both polarized 
effector T cells and FOXP3+ regulatory T cells. J Immunol. 
2008; 180:122-9.
26. Moens U, Seternes OM, Johansen B, Rekvig OP. 
Mechanisms of transcriptional regulation of cellular genes 
by SV40 large T- and small T-antigens. Virus Genes. 1997; 
15:135-54.
27. Atwood WJ, Wang L, Durham LC, Amemiya K, Traub RG, 
Major EO. Evaluation of the role of cytokine activation in 
the multiplication of JC virus (JCV) in human fetal glial 
cells. J Neurovirol. 1995; 1:40-9.
28. Kim SY, Choi EC, Woo Jo Y, Henson JW, Kim HS. 
Transcriptional activation of JC virus early promoter 
by phorbol ester and interleukin-1beta: critical 
role of nuclear factor-1. Virology. 2004; 327:60-9. 
https://doi.org/10.1016/j.virol.2004.06.021.
29. Enam S, Sweet TM, Amini S, Khalili K, Del Valle L. 
Evidence for involvement of transforming growth factor 
beta1 signaling pathway in activation of JC virus in human 
immunodeficiency virus 1-associated progressive multifocal 
leukoencephalopathy. Arch Pathol Lab Med. 2004; 128:282-91. 
https://doi.org/10.1043/1543-2165(2004)128<282:EFIOTG>2.0.CO;2.
30. Abend JR, Imperiale MJ. Transforming growth factor-beta-
mediated regulation of BK virus gene expression. Virology. 
2008; 378:6-12. https://doi.org/10.1016/j.virol.2008.05.009.
31. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher 
EC. CC chemokine receptor (CCR)4 and the CCR10 
ligand cutaneous T cell-attracting chemokine (CTACK) in 
lymphocyte trafficking to inflamed skin. J Exp Med. 2001; 
194:1541-7.
32. Vestergaard C, Johansen C, Christensen U, Just H, Hohwy T, 
Deleuran M. TARC augments TNF-alpha-induced CTACK 
production in keratinocytes. Exp Dermatol. 2004; 13:551-7. 
https://doi.org/10.1111/j.0906-6705.2004.00202.x.
33. Johansen C, Kragballe K, Westergaard M, Henningsen 
J, Kristiansen K, Iversen L. The mitogen-activated 
protein kinases p38 and ERK1/2 are increased in 
lesional psoriatic skin. Br J Dermatol. 2005; 152:37-42. 
https://doi.org/10.1111/j.1365-2133.2004.06304.x.
34. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. 
Chemokines in tumor progression and metastasis. Oncotarget. 
2013; 4:2171-85. https://doi.org/10.18632/oncotarget.1426.
35. Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, 
Akagi K, Thakuria M, Rabinowits G, Wang LC, Symer DE, 
Pipas JM, Harris RS, DeCaprio JA. Merkel cell polyomavirus 
exhibits dominant control of the tumor genome and 
transcriptome in virus-associated merkel cell carcinoma. MBio. 
2017; 8:e02079-16. https://doi.org/10.1128/mBio.02079-16.
36. Griffiths DA, Abdul-Sada H, Knight LM, Jackson BR, 
Richards K, Prescott EL, Peach AH, Blair GE, Macdonald 
A, Whitehouse A. Merkel cell polyomavirus small T 
antigen targets the NEMO adaptor protein to disrupt 
inflammatory signaling. J Virol. 2013; 87:13853-67. 
https://doi.org/10.1128/JVI.02159-13.
37. Richards KF, Guastafierro A, Shuda M, Toptan T, Moore 
PS, Chang Y. Merkel cell polyomavirus T antigens 
promote cell proliferation and inflammatory cytokine 
gene expression. J Gen Virol. 2015; 96:3532-44. 
https://doi.org/10.1099/jgv.0.000287.
38. Kumai T, Nagato T, Kobayashi H, Komabayashi Y, Ueda 
S, Kishibe K, Ohkuri T, Takahara M, Celis E, Harabuchi Y. 
CCL17 and CCL22/CCR4 signaling is a strong candidate 
for novel targeted therapy against nasal natural killer/T-cell 
lymphoma. Cancer Immunol Immunother. 2015; 64:697-
705. https://doi.org/10.1007/s00262-015-1675-7.
Oncotarget31446www.oncotarget.com
39. Niens M, Visser L, Nolte IM, van der Steege G, 
Diepstra A, Cordano P, Jarrett RF, Te Meerman GJ, 
Poppema S, van den Berg A. Serum chemokine levels in 
Hodgkin lymphoma patients: highly increased levels of 
CCL17 and CCL22. Br J Haematol. 2008; 140:527-36. 
https://doi.org/10.1111/j.1365-2141.2007.06964.x.
40. Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima 
K, Nagakubo D, Shirakawa AK, Tsuzuki T, Nakamura 
S, Yoshie O. Expression of CCL17 and CCL22 by 
latent membrane protein 1-positive tumor cells in 
age-related Epstein-Barr virus-associated B-cell 
lymphoproliferative disorder. Cancer Sci. 2008; 99:296-302. 
https://doi.org/10.1111/j.1349-7006.2007.00687.x.
41. Liu LB, Xie F, Chang KK, Shang WQ, Meng YH, Yu JJ, 
Li H, Sun Q, Yuan MM, Jin LP, Li DJ, Li MQ. Chemokine 
CCL17 induced by hypoxia promotes the proliferation of 
cervical cancer cell. Am J Cancer Res. 2015; 5:3072-84.
42. Al-haidari AA, Syk I, Jirstrom K, Thorlacius H. 
CCR4 mediates CCL17 (TARC)-induced migration 
of human colon cancer cells via RhoA/Rho-kinase 
signaling. Int J Colorectal Dis. 2013; 28:1479-87. 
https://doi.org/10.1007/s00384-013-1712-y.
43. Zhu F, Li X, Chen S, Zeng Q, Zhao Y, Luo F. 
Tumor-associated macrophage or chemokine ligand 
CCL17 positively regulates the tumorigenesis of 
hepatocellular carcinoma. Med Oncol. 2016; 33:17. 
https://doi.org/10.1007/s12032-016-0729-9.
44. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura 
K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within 
tumor microenvironment are related to accumulation of 
Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 
2008; 122:2286-93. https://doi.org/10.1002/ijc.23392.
45. Maruyama T, Kono K, Izawa S, Mizukami Y, Kawaguchi 
Y, Mimura K, Watanabe M, Fujii H. CCL17 and CCL22 
chemokines within tumor microenvironment are related 
to infiltration of regulatory T cells in esophageal 
squamous cell carcinoma. Dis Esophagus. 2010; 23:422-9. 
https://doi.org/10.1111/j.1442-2050.2009.01029.x.
46. Liu W, Wei X, Li L, Wu X, Yan J, Yang H, Song F. 
CCR4 mediated chemotaxis of regulatory T cells 
suppress the activation of T cells and NK cells via TGF-
beta pathway in human non-small cell lung cancer. 
Biochem Biophys Res Commun. 2017; 488:196-203. 
https://doi.org/10.1016/j.bbrc.2017.05.034.
47. Moens U, Calvignac-Spencer S, Lauber C, Ramqvist 
T, Feltkamp MCW, Daugherty MD, Verschoor EJ, 
Ehlers B, Ictv Report C. ICTV virus taxonomy profile: 
polyomaviridae. J Gen Virol. 2017; 98:1159-60. 
https://doi.org/10.1099/jgv.0.000839.
48. Messeguer X, Escudero R, Farre D, Nunez O, Martinez 
J, Alba MM. PROMO: detection of known transcription 
regulatory elements using species-tailored searches. 
Bioinformatics. 2002; 18:333-4.
49. Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama 
M, Kawa K, Yoshie O. Selective induction of Th2-attracting 
chemokines CCL17 and CCL22 in human B cells by latent 
membrane protein 1 of Epstein-Barr virus. J Virol. 2004; 
78:1665-74.
50. Monick MM, Powers LS, Hassan I, Groskreutz D, 
Yarovinsky TO, Barrett CW, Castilow EM, Tifrea D, 
Varga SM, Hunninghake GW. Respiratory syncytial virus 
synergizes with Th2 cytokines to induce optimal levels of 
TARC/CCL17. J Immunol. 2007; 179:1648-58.
51. Ueda R. Clinical Application of Anti-CCR4 
Monoclonal Antibody. Oncology. 2015; 89:16-21. 
https://doi.org/10.1159/000431059.
52. Ou B, Zhao J, Guan S, Feng H, Wangpu X, Zhu 
C, Zong Y, Ma J, Sun J, Shen X, Zheng M, Lu A. 
CCR4 promotes metastasis via ERK/NF-kappaB/
MMP13 pathway and acts downstream of TNF-alpha 
in colorectal cancer. Oncotarget. 2016; 7:47637-49. 
https://doi.org/10.18632/oncotarget.10256.
53. Li JY, Ou ZL, Yu SJ, Gu XL, Yang C, Chen AX, Di GH, 
Shen ZZ, Shao ZM. The chemokine receptor CCR4 
promotes tumor growth and lung metastasis in breast 
cancer. Breast Cancer Res Treat. 2012; 131:837-48. 
https://doi.org/10.1007/s10549-011-1502-6.
54. Olkhanud PB, Baatar D, Bodogai M, Hakim F, 
Gress R, Anderson RL, Deng J, Xu M, Briest S, 
Biragyn A. Breast cancer lung metastasis requires 
expression of chemokine receptor CCR4 and 
regulatory T cells. Cancer Res. 2009; 69:5996-6004. 
https://doi.org/10.1158/0008-5472.CAN-08-4619.
55. Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, 
Arita Y, Nakayama T, Sakurai H, Yoshie O, Saiki 
I. RANKL-induced CCL22/macrophage-derived 
chemokine produced from osteoclasts potentially 
promotes the bone metastasis of lung cancer expressing 
its receptor CCR4. Clin Exp Metastasis. 2006; 23:9-18. 
https://doi.org/10.1007/s10585-006-9006-1.
56. Lee JH, Cho YS, Lee JY, Kook MC, Park JW, Nam BH, 
Bae JM. The chemokine receptor CCR4 is expressed 
and associated with a poor prognosis in patients 
with gastric cancer. Ann Surg. 2009; 249:933-41. 
https://doi.org/10.1097/SLA.0b013e3181a77ccc.
57. Ishida T, Ueda R. CCR4 as a novel molecular target for 
immunotherapy of cancer. Cancer Sci. 2006; 97:1139-46. 
https://doi.org/10.1111/j.1349-7006.2006.00307.x.
58. Leonard JH, Ramsay JR, Kearsley JH, Birrell GW. 
Radiation sensitivity of Merkel cell carcinoma cell 
lines. Int J Radiat Oncol Biol Phys. 1995; 32:1401-7. 
https://doi.org/10.1016/0360-3016(94)00610-W.
59. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, 
Moore PS, Chang Y. T antigen mutations are a human 
tumor-specific signature for Merkel cell polyomavirus. 
Proc Natl Acad Sci U S A. 2008; 105:16272-7. 
https://doi.org/10.1073/pnas.0806526105.
60. Figenschau Y, Knutsen G, Shahazeydi S, Johansen O, 
Sveinbjornsson B. Human articular chondrocytes express 
Oncotarget31447www.oncotarget.com
functional leptin receptors. Biochem Biophys Res Commun. 
2001; 287:190-7. https://doi.org/10.1006/bbrc.2001.5543.
61. Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely 
S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, 
Hoon DSB, Erez N, Witz IP. CCR4 is a determinant of 
melanoma brain metastasis. Oncotarget. 2017; 8:31079-91. 
https://doi.org/10.18632/oncotarget.16076.
62. Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto 
K, Matsuda A. Expression of thymus and activation-
regulated chemokine (TARC) by human dermal cells, but 
not epidermal keratinocytes. J Dermatol Sci. 2014; 76:90-5. 
https://doi.org/10.1016/j.jdermsci.2014.08.009.
63. McCully ML, Moser B. The human cutaneous 
chemokine system. Front Immunol. 2011; 2:33. 
https://doi.org/10.3389/fimmu.2011.00033.
64. Fujimoto S, Uratsuji H, Saeki H, Kagami S, Tsunemi 
Y, Komine M, Tamaki K. CCR4 and CCR10 are 
expressed on epidermal keratinocytes and are involved in 
cutaneous immune reaction. Cytokine. 2008; 44:172-8. 
https://doi.org/10.1016/j.cyto.2008.07.472.
65. Stutte S, Quast T, Gerbitzki N, Savinko T, Novak 
N, Reifenberger J, Homey B, Kolanus W, Alenius 
H, Forster I. Requirement of CCL17 for CCR7- and 
CXCR4-dependent migration of cutaneous dendritic 
cells. Proc Natl Acad Sci U S A. 2010; 107:8736-41. 
https://doi.org/10.1073/pnas.0906126107.
66. Moroi Y, Yu B, Urabe K, Koga T, Nakahara T, Dainichi T, 
Uchi H, Furue M. Effects of MAPK inhibitors on CCR4-
mediated chemotaxis against thymus and activation-
regulated chemokine (TARC/CCL17). J Dermatol Sci. 2004; 
36:186-8. https://doi.org/10.1016/j.jdermsci.2004.08.013.
67. Berin MC, Eckmann L, Broide DH, Kagnoff MF. Regulated 
production of the T helper 2-type T-cell chemoattractant 
TARC by human bronchial epithelial cells in vitro and in 
human lung xenografts. Am J Respir Cell Mol Biol. 2001; 
24:382-9. https://doi.org/10.1165/ajrcmb.24.4.4360.
68. Bouffi C, Rochman M, Zust CB, Stucke EM, Kartashov A, 
Fulkerson PC, Barski A, Rothenberg ME. IL-33 markedly 
activates murine eosinophils by an NF-kappaB-dependent 
mechanism differentially dependent upon an IL-4-driven 
autoinflammatory loop. J Immunol. 2013; 191:4317-25. 
https://doi.org/10.4049/jimmunol.1301465.
69. Li G, Li GY, Wang ZZ, Ji HJ, Wang DM, Hu JF, Yuan YH, 
Liu G, Chen NH. The chemokine-like factor 1 induces 
asthmatic pathological change by activating nuclear factor-
kappaB signaling pathway. Int Immunopharmacol. 2014; 
20:81-8. https://doi.org/10.1016/j.intimp.2014.02.014.
70. Ness TL, Ewing JL, Hogaboam CM, Kunkel SL. CCR4 is 
a key modulator of innate immune responses. J Immunol. 
2006; 177:7531-9.
71. Vermeer MH, Dukers DF, ten Berge RL, Bloemena 
E, Wu L, Vos W, de Vries E, Tensen CP, Meijer CJ, 
Willemze R. Differential expression of thymus and 
activation regulated chemokine and its receptor CCR4 
in nodal and cutaneous anaplastic large-cell lymphomas 
and Hodgkin’s disease. Mod Pathol. 2002; 15:838-44. 
https://doi.org/10.1097/01.MP.0000021006.53593.B0.
72. Bayry J, Tartour E, Tough DF. Targeting CCR4 
as an emerging strategy for cancer therapy and 
vaccines. Trends Pharmacol Sci. 2014; 35:163-5. 
https://doi.org/10.1016/j.tips.2014.02.003.
73. Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang 
Y, Yu X, Waldmann TA, Staudt LM. Gain-of-function CCR4 
mutations in adult T cell leukemia/lymphoma. J Exp Med. 
2014; 211:2497-505. https://doi.org/10.1084/jem.20140987.
74. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, 
Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada 
S, Tamura K, Nakamura S, Inagaki H, Ohshima K, 
et al. Phase I study of KW-0761, a defucosylated 
humanized anti-CCR4 antibody, in relapsed patients 
with adult T-cell leukemia-lymphoma and peripheral 
T-cell lymphoma. J Clin Oncol. 2010; 28:1591-8. 
https://doi.org/10.1200/JCO.2009.25.3575.
75. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya 
A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, 
Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, et al. 
Defucosylated anti-CCR4 monoclonal antibody (KW-
0761) for relapsed adult T-cell leukemia-lymphoma: a 
multicenter phase II study. J Clin Oncol. 2012; 30:837-42. 
https://doi.org/10.1200/JCO.2011.37.3472.
76. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, 
Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, 
Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, et al. 
Multicenter phase II study of mogamulizumab (KW-0761), 
a defucosylated anti-cc chemokine receptor 4 antibody, 
in patients with relapsed peripheral T-cell lymphoma and 
cutaneous T-cell lymphoma. J Clin Oncol. 2014; 32:1157-
63. https://doi.org/10.1200/JCO.2013.52.0924.
77. Solari R, Pease JE. Targeting chemokine receptors in 
disease--a case study of CCR4. Eur J Pharmacol. 2015; 
763:169-77. https://doi.org/10.1016/j.ejphar.2015.05.018.
78. Tobinai K, Takahashi T, Akinaga S. Targeting chemokine 
receptor CCR4 in adult T-cell leukemia-lymphoma and 
other T-cell lymphomas. Curr Hematol Malig Rep. 2012; 
7:235-40. https://doi.org/10.1007/s11899-012-0124-3.
79. Maier E, Wirnsberger G, Horejs-Hoeck J, Duschl A, 
Hebenstreit D. Identification of a distal tandem STAT6 
element within the CCL17 locus. Hum Immunol. 2007; 
68:986-92. https://doi.org/10.1016/j.humimm.2007.10.012.
80. Mosmann T. Rapid colorimetric assay for cellular growth 
and survival: application to proliferation and cytotoxicity 
assays. J Immunol Methods. 1983; 65:55-63.
